Handelsbanken Fonder AB Has $11.52 Million Holdings in Moderna, Inc. (NASDAQ:MRNA)

Handelsbanken Fonder AB lessened its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 43.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 115,828 shares of the company’s stock after selling 89,169 shares during the quarter. Handelsbanken Fonder AB’s holdings in Moderna were worth $11,519,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the business. CWM LLC raised its stake in Moderna by 27.1% during the 4th quarter. CWM LLC now owns 118,335 shares of the company’s stock worth $11,768,000 after buying an additional 25,209 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd increased its holdings in Moderna by 1.1% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 28,969 shares of the company’s stock worth $2,881,000 after purchasing an additional 306 shares in the last quarter. APEIRON CAPITAL Ltd increased its holdings in Moderna by 96.2% during the 4th quarter. APEIRON CAPITAL Ltd now owns 31,200 shares of the company’s stock worth $3,103,000 after purchasing an additional 15,300 shares in the last quarter. Lindbrook Capital LLC increased its holdings in Moderna by 41.9% during the 4th quarter. Lindbrook Capital LLC now owns 1,391 shares of the company’s stock worth $138,000 after purchasing an additional 411 shares in the last quarter. Finally, abrdn plc increased its holdings in Moderna by 477.5% during the 4th quarter. abrdn plc now owns 483,574 shares of the company’s stock worth $48,091,000 after purchasing an additional 399,843 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Activity at Moderna

In other news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $109.06, for a total transaction of $1,635,900.00. Following the transaction, the director now owns 2,101,931 shares in the company, valued at $229,236,594.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Shannon Thyme Klinger sold 670 shares of the company’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $63,361.90. Following the sale, the insider now owns 8,557 shares in the company, valued at approximately $809,235.49. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $109.06, for a total transaction of $1,635,900.00. Following the completion of the sale, the director now owns 2,101,931 shares in the company, valued at approximately $229,236,594.86. The disclosure for this sale can be found here. Insiders have sold a total of 109,954 shares of company stock worth $11,533,976 over the last quarter. Company insiders own 15.20% of the company’s stock.

Moderna Stock Performance

NASDAQ MRNA opened at $107.89 on Wednesday. The firm’s fifty day moving average price is $101.39 and its two-hundred day moving average price is $93.53. The stock has a market cap of $41.31 billion, a PE ratio of -8.69 and a beta of 1.62. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $142.79. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of ($0.78) by $1.33. The company had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. Moderna’s revenue for the quarter was down 44.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.61 earnings per share. On average, equities analysts expect that Moderna, Inc. will post -7.51 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a report on Thursday, April 11th. Jefferies Financial Group reiterated a “buy” rating and set a $125.00 target price on shares of Moderna in a report on Tuesday, April 9th. William Blair reiterated a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Royal Bank of Canada restated an “outperform” rating and issued a $125.00 price objective on shares of Moderna in a report on Thursday, March 28th. Finally, HSBC restated a “reduce” rating and issued a $86.00 price objective (up previously from $75.00) on shares of Moderna in a report on Monday, February 26th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $126.49.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.